We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Miller

David M. Miller MD, PhD, FAAD

Director, Center for Merkel Cell Carcinoma; Co-Director, NMSC Multi-Disciplinary Clinic, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, Massachusetts General Cancer Center, Boston, Massachusetts

David M. Miller, MD, PhD, is a board-certified Internist, Dermatologist and Medical Oncologist.

Dr. Miller graduated with Honors from Boston College where he earned a BA in Political Science. He received his medical (MD) and PhD degree in Biomedical Sciences from the University of Massachusetts. He then completed a Dermatology residency at Columbia University Medical Center, followed by a residency in Internal Medicine at Brigham and Women's Hospital. Following both residencies, Dr. Miller completed fellowship training in Hematology/Oncology at Beth Israel Deaconess Medical Center and in the Oncology Center of Excellence at the Food and Drug Administration (FDA).

Dr. Miller is one of the very few clinicians in the entire country who is board certified in Internal Medicine, Dermatology and Medical Oncology. He currently practices both Dermatology and Medical Oncology in the MGH Cancer Center and at Massachusetts Eye and Ear Infirmary, where he directs the Center for Merkel Cell Carcinoma and co-directs multidisciplinary clinics in advanced skin cancer. He is the principal investigator of a clinical and translational research laboratory investigating novel therapies for non-melanoma skin cancer.

Disclosures

Dr. Miller has received honoraria for participation on advisory boards for Merck, EMD Serono, Regeneron, Sanofi Genzyme, Pfizer, Castle Biosciences and Checkpoint Therapeutics. He has stock in Checkpoint Therapeutics. He has received funding from Project Data Sphere, ECOG-ACRIN and the American Skin Association.